NEW YORK and CLEVELAND, Jan 20 (Bernama-GLOBE NEWSWIRE) --
Abeona Therapeutics Inc. (Nasdaq:ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/226/16) for Abeona’s gene therapy program ABO-101 for children impacted by Sanfilippo syndrome type B (MPS IIIB), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death in children. mrem.bernama.com/viewsm.php?idm=28311
0 Comments
Leave a Reply. |
Archives
April 2023
|